Orange Book product · Generic (ANDA)
LAMIVUDINE
LAMIVUDINE
At a glance
Mar 21, 2019
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 21, 2019
7 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
LAMIVUDINE
Strength
100MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 211306
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LAMIVUDINE
- 1998EPIVIR-HBVBrand (NDA)
NDA 021004 · GLAXOSMITHKLINE
- 1998EPIVIR-HBVBrand (NDA)
NDA 021003 · GLAXOSMITHKLINE
- 1995EPIVIRBrand (NDA)
NDA 020596 · VIIV HLTHCARE
- 1995EPIVIRBrand (NDA)
NDA 020564 · VIIV HLTHCARE
- 2023LAMIVUDINEGeneric (ANDA)
ANDA 091475 · HETERO LABS LTD III
- 2019LAMIVUDINEGeneric (ANDA)
ANDA 090198 · MACLEODS PHARMS LTD
- 2019LAMIVUDINEGeneric (ANDA)
ANDA 078545 · PHARMOBEDIENT
- 2018LAMIVUDINEGeneric (ANDA)
ANDA 090457 · STRIDES PHARMA
- 2017LAMIVUDINEGeneric (ANDA)
ANDA 077221 · CIPLA
- 2016LAMIVUDINEGeneric (ANDA)
ANDA 077695 · AUROBINDO PHARMA
- 2016LAMIVUDINEGeneric (ANDA)
ANDA 077464 · AUROBINDO PHARMA
- 2016LAMIVUDINEGeneric (ANDA)
ANDA 203586 · BRECKENRIDGE
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
